| Dr Ronald G Wright, DDS | |
|
514 Delaware St, Hiawatha, KS 66434-2118 | |
| (785) 742-2165 | |
| (785) 742-3411 |
| Full Name | Dr Ronald G Wright |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 514 Delaware St, Hiawatha, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790750958 | NPI | - | NPPES |
| WR547795 | Medicaid | KS | |
| 8419 | Other | KS | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 5728 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ronald G Wright, DDS 514 Delaware St, Hiawatha, KS 66434-2118 Ph: (785) 742-2165 | Dr Ronald G Wright, DDS 514 Delaware St, Hiawatha, KS 66434-2118 Ph: (785) 742-2165 |
News Archive
Lowering an infant's body temperature to about 92 degrees Fahrenheit within the first six hours of life reduces the chances for disability and death among infants who failed to receive enough oxygen or blood to the brain during birth. The research study findings appear in tomorrow's 2005 New England Journal of Medicine.
VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.
Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
The fear of public speaking is the most common among individuals with SAD, as well as in the general population. The results of the study are published in the March issue of the Archives of General Psychiatry.
› Verified 8 days ago
Dr. Sean Michael Fay, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 107 S 6th St, Hiawatha, KS 66434 Phone: 785-742-3512 Fax: 785-742-3512 | |
Dr. Jordan Danell Haedt, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 514 Delaware St, Hiawatha, KS 66434 Phone: 785-742-2165 |